Cargando…
Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods
BACKGROUND: Preventing progression to moderate or severe opioid use disorder (OUD) among people who exhibit risky opioid use behavior that does not meet criteria for treatment with opioid agonists or antagonists (subthreshold OUD) is poorly understood. The Subthreshold Opioid Use Disorder Prevention...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657560/ https://www.ncbi.nlm.nih.gov/pubmed/37980494 http://dx.doi.org/10.1186/s13722-023-00424-8 |
_version_ | 1785148174127595520 |
---|---|
author | Liebschutz, Jane M. Subramaniam, Geetha A. Stone, Rebecca Appleton, Noa Gelberg, Lillian Lovejoy, Travis I. Bunting, Amanda M. Cleland, Charles M. Lasser, Karen E. Beers, Donna Abrams, Catherine McCormack, Jennifer Potter, Gail E. Case, Ashley Revoredo, Leslie Jelstrom, Eve M. Kline, Margaret M. Wu, Li-Tzy McNeely, Jennifer |
author_facet | Liebschutz, Jane M. Subramaniam, Geetha A. Stone, Rebecca Appleton, Noa Gelberg, Lillian Lovejoy, Travis I. Bunting, Amanda M. Cleland, Charles M. Lasser, Karen E. Beers, Donna Abrams, Catherine McCormack, Jennifer Potter, Gail E. Case, Ashley Revoredo, Leslie Jelstrom, Eve M. Kline, Margaret M. Wu, Li-Tzy McNeely, Jennifer |
author_sort | Liebschutz, Jane M. |
collection | PubMed |
description | BACKGROUND: Preventing progression to moderate or severe opioid use disorder (OUD) among people who exhibit risky opioid use behavior that does not meet criteria for treatment with opioid agonists or antagonists (subthreshold OUD) is poorly understood. The Subthreshold Opioid Use Disorder Prevention (STOP) Trial is designed to study the efficacy of a collaborative care intervention to reduce risky opioid use and to prevent progression to moderate or severe OUD in adult primary care patients with subthreshold OUD. METHODS: The STOP trial is a cluster randomized controlled trial, randomized at the PCP level, conducted in 5 distinct geographic sites. STOP tests the efficacy of the STOP intervention in comparison to enhanced usual care (EUC) in adult primary care patients with risky opioid use that does not meet criteria for moderate-severe OUD. The STOP intervention consists of (1) a practice-embedded nurse care manager (NCM) who provides patient participant education and supports primary care providers (PCPs) in engaging and monitoring patient-participants; (2) brief advice, delivered to patient participants by their PCP and/or prerecorded video message, about health risks of opioid misuse; and (3) up to 6 sessions of telephone health coaching to motivate and support behavior change. EUC consists of primary care treatment as usual, plus printed overdose prevention educational materials and an educational video on cancer screening. The primary outcome measure is self-reported number of days of risky (illicit or nonmedical) opioid use over 180 days, assessed monthly via text message using items from the Addiction Severity Index and the Current Opioid Misuse Measure. Secondary outcomes assess other substance use, mental health, quality of life, and healthcare utilization as well as PCP prescribing and monitoring behaviors. A mixed effects negative binomial model with a log link will be fit to estimate the difference in means between treatment and control groups using an intent-to-treat population. DISCUSSION: Given a growing interest in interventions for the management of patients with risky opioid use, and the need for primary care-based interventions, this study potentially offers a blueprint for a feasible and effective approach to improving outcomes in this population. Trial Registration: Clinicaltrials.gov, identifier NCT04218201, January 6, 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13722-023-00424-8. |
format | Online Article Text |
id | pubmed-10657560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106575602023-11-18 Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods Liebschutz, Jane M. Subramaniam, Geetha A. Stone, Rebecca Appleton, Noa Gelberg, Lillian Lovejoy, Travis I. Bunting, Amanda M. Cleland, Charles M. Lasser, Karen E. Beers, Donna Abrams, Catherine McCormack, Jennifer Potter, Gail E. Case, Ashley Revoredo, Leslie Jelstrom, Eve M. Kline, Margaret M. Wu, Li-Tzy McNeely, Jennifer Addict Sci Clin Pract Study Protocol BACKGROUND: Preventing progression to moderate or severe opioid use disorder (OUD) among people who exhibit risky opioid use behavior that does not meet criteria for treatment with opioid agonists or antagonists (subthreshold OUD) is poorly understood. The Subthreshold Opioid Use Disorder Prevention (STOP) Trial is designed to study the efficacy of a collaborative care intervention to reduce risky opioid use and to prevent progression to moderate or severe OUD in adult primary care patients with subthreshold OUD. METHODS: The STOP trial is a cluster randomized controlled trial, randomized at the PCP level, conducted in 5 distinct geographic sites. STOP tests the efficacy of the STOP intervention in comparison to enhanced usual care (EUC) in adult primary care patients with risky opioid use that does not meet criteria for moderate-severe OUD. The STOP intervention consists of (1) a practice-embedded nurse care manager (NCM) who provides patient participant education and supports primary care providers (PCPs) in engaging and monitoring patient-participants; (2) brief advice, delivered to patient participants by their PCP and/or prerecorded video message, about health risks of opioid misuse; and (3) up to 6 sessions of telephone health coaching to motivate and support behavior change. EUC consists of primary care treatment as usual, plus printed overdose prevention educational materials and an educational video on cancer screening. The primary outcome measure is self-reported number of days of risky (illicit or nonmedical) opioid use over 180 days, assessed monthly via text message using items from the Addiction Severity Index and the Current Opioid Misuse Measure. Secondary outcomes assess other substance use, mental health, quality of life, and healthcare utilization as well as PCP prescribing and monitoring behaviors. A mixed effects negative binomial model with a log link will be fit to estimate the difference in means between treatment and control groups using an intent-to-treat population. DISCUSSION: Given a growing interest in interventions for the management of patients with risky opioid use, and the need for primary care-based interventions, this study potentially offers a blueprint for a feasible and effective approach to improving outcomes in this population. Trial Registration: Clinicaltrials.gov, identifier NCT04218201, January 6, 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13722-023-00424-8. BioMed Central 2023-11-18 2023 /pmc/articles/PMC10657560/ /pubmed/37980494 http://dx.doi.org/10.1186/s13722-023-00424-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Liebschutz, Jane M. Subramaniam, Geetha A. Stone, Rebecca Appleton, Noa Gelberg, Lillian Lovejoy, Travis I. Bunting, Amanda M. Cleland, Charles M. Lasser, Karen E. Beers, Donna Abrams, Catherine McCormack, Jennifer Potter, Gail E. Case, Ashley Revoredo, Leslie Jelstrom, Eve M. Kline, Margaret M. Wu, Li-Tzy McNeely, Jennifer Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods |
title | Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods |
title_full | Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods |
title_fullStr | Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods |
title_full_unstemmed | Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods |
title_short | Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods |
title_sort | subthreshold opioid use disorder prevention (stop) trial: a cluster randomized clinical trial: study design and methods |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657560/ https://www.ncbi.nlm.nih.gov/pubmed/37980494 http://dx.doi.org/10.1186/s13722-023-00424-8 |
work_keys_str_mv | AT liebschutzjanem subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT subramaniamgeethaa subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT stonerebecca subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT appletonnoa subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT gelberglillian subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT lovejoytravisi subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT buntingamandam subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT clelandcharlesm subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT lasserkarene subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT beersdonna subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT abramscatherine subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT mccormackjennifer subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT pottergaile subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT caseashley subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT revoredoleslie subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT jelstromevem subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT klinemargaretm subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT wulitzy subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods AT mcneelyjennifer subthresholdopioidusedisorderpreventionstoptrialaclusterrandomizedclinicaltrialstudydesignandmethods |